Debra K. Frye
46 works · 4,263 citations · h-index 22
Top works
- THE IMPACT OF NATIONAL CANCER ACT
- Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
- Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks
- Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy With Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients With Operable Breast Cancer
- Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma
- c-erbB-2 amplification in node-negative human breast cancer.
- Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
- Combined Modality Treatment of Stage III and Inflammatory Breast Cancer
- Long-Term Results of Combined-Modality Therapy for Locally Advanced Breast Cancer With Ipsilateral Supraclavicular Metastases: The University of Texas M.D. Anderson Cancer Center Experience
- The Use of Alternate, Non–Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-Term Results From a Prospective Randomized Trial
- Inflammatory carcinoma of the breast: results of a combined-modality approach ? M. D. Anderson Cancer Center experience
- Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer a prospective, randomized trial
- A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma
- Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer
- Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience
- p53 and c-erbB-2 expression and response to preoperative chemotherapy in locally advanced breast carcinoma
- Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy.
- Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy
- First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study
- Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer